Compare APC & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APC | SDGR |
|---|---|---|
| Founded | 2025 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 892.9M | 850.5M |
| IPO Year | N/A | 2020 |
| Metric | APC | SDGR |
|---|---|---|
| Price | $18.43 | $12.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $21.75 | $21.00 |
| AVG Volume (30 Days) | 125.3K | ★ 1.2M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 11.03% | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | $4.47 | $0.76 |
| Revenue Next Year | $4.20 | $4.60 |
| P/E Ratio | $25.80 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $17.08 | $10.95 |
| 52 Week High | $19.80 | $27.63 |
| Indicator | APC | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 47.05 | 61.42 |
| Support Level | $17.32 | $11.03 |
| Resistance Level | $19.01 | $13.36 |
| Average True Range (ATR) | 0.56 | 0.58 |
| MACD | -0.00 | 0.19 |
| Stochastic Oscillator | 45.51 | 95.63 |
Arko Petroleum Corp is a fuel distribution company. It operates through three reportable segments: i) Wholesale: Distributes fuel to gas stations, sub-wholesalers, and bulk purchasers, typically under long-term contracts on a cost-plus or consignment basis. ii) Fleet Fueling: Operates proprietary and third-party cardlock locations serving commercial and municipal fleets, and earns commissions from proprietary fuel card sales. iii) GPMP: Supplies fuel to ARKO Retail Sites at cost plus a fixed margin, charges fixed fees to certain sites. The company generates the majority of revenue from the Wholesale segment.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.